China Target Of Boehringer $149 Million Vaccine-Drug Investment
This article was originally published in PharmAsia News
Executive SummaryChina has drawn another large pharmaceutical company investment, this one from Germany's Boehringer Ingelheim, which plans to spend $149 million
You may also be interested in...
FDA warns OHM Pharma for promoting topical formula containing homeopathic ingredients as teething product for infants. The firm also warned about drug and supplements GMP violations and was an easy target for FDA following release of draft guidance outlining its enforcement priorities.
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.